drugset / Trial / NCT07144163
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
Timeline
- Start
- 2025-12-11
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atumelnant | Small molecule | 80 mg | Oral |
| Subject | Atumelnant | Small molecule | 120 mg | Oral |